APLI — Appili Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- CA$5.46m
- CA$12.87m
- CA$0.33m
Annual cashflow statement for Appili Therapeutics, fiscal year end - March 31st, CAD millions except per share, conversion factor applied.
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -4.33 | -5.42 | -14.3 | -25.1 | -9.24 |
| Depreciation | |||||
| Non-Cash Items | 0.546 | 0.694 | 1.22 | 3.54 | 2.37 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.307 | 0.444 | 1.64 | 2.49 | -3.24 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -3.46 | -4.26 | -11.5 | -19.1 | -10.1 |
| Capital Expenditures | -0.013 | -0.001 | -0.008 | 0 | -0.003 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -0 | -0 | -4.98 | 5.06 | 0 |
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.013 | -0.001 | -4.99 | 5.06 | -0.003 |
| Financing Cash Flow Items | -0.59 | -1.12 | -1.42 | -1.31 | -1.01 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 3.06 | 9.36 | 17 | 9.56 | 5.91 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.3 | 5.09 | 0.553 | -4.4 | -4.2 |